Ivan Henriquez

Oncologia

[Ivan Henriquez @ivanh1960]

It was an honor to have participated with national and international colleagues in this great prostate cancer meeting.

[Ivan Henriquez @ivanh1960]

It was an honor to have participated with national and international colleagues in this great prostate cancer meeting.

[Ivan Henriquez @ivanh1960]

Our last paper is out!. It was an honor to participate in this international project !!. article link:
https://t.co/mcx3UFE8gg

[Ivan Henriquez @ivanh1960]

Our last paper is out!. It was an honor to participate in this international project !!. article link:
https://t.co/mcx3UFE8gg

[Ivan Henriquez @ivanh1960]

Our last opinion article “is out!!”. We still believe there are some oncological reasons to support pelvic RT… beyond the volume…https://t.co/BAQBenRa86

[Ivan Henriquez @ivanh1960]

Our last opinion article “is out!!”. We still believe there are some oncological reasons to support pelvic RT… beyond the volume…https://t.co/BAQBenRa86

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

The diagnostic value of mpMRI and PSMA-targeted PET/CT in radiorecurrent prostate cancer: a narrative review

https://t.co/HvsVxDc1WT

Review evaluates mpMRI and PSMA-targeted PET/CT for restaging radiorecurrent #ProstateCancer after radiotherapy☢️

Across 10 studies, mpMRI showed moderate-to-high specificity but variable sensitivity, often underestimating multifocal disease. PSMA-targeted PET/CT demonstrated high sensitivity for intraprostatic recurrence and superior detection of nodal and distant metastases.

Combined imaging achieved the highest diagnostic confidence, supporting improved patient selection for salvage therapy, although histologic confirmation remains essential before treatment.

Umberto Merani
@AMarquis_MD
@GMarra_MD
@paolo_gontero
@oderdam

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists

[Ivan Henriquez @ivanh1960]

Enhorabuena!!!

[Virginia Ruiz @roentgen66]

Agradecida. Tu historia no acaba aquí, elegida finalista en los Premios GEPAC 2026 (categoría labor periodística o labor literaria más comprometida con la normalización social del cáncer).

📍 El fallo será el 23 de abril Palacio de la Prensa, Madrid

#GEPAC #OncologiaConAlma

[Ivan Henriquez @ivanh1960]

Our last paper is out!!
ERG expression is not predictive of outcome in patients with intermediate- and high-risk localized prostate cancer treated with combined androgen blockade and radiotherapy https://t.co/LIYPlF7RkB

[Ivan Henriquez @ivanh1960]

Our last paper is out!!
ERG expression is not predictive of outcome in patients with intermediate- and high-risk localized prostate cancer treated with combined androgen blockade and radiotherapy https://t.co/LIYPlF7RkB

[Ivan Henriquez @ivanh1960]

On the role of the Prolaris genomic platform in prostate cancer management.
Honored to have contributed to this international collaborative effort (ASCO-GU 2026!).

[Ivan Henriquez @ivanh1960]

On the role of the Prolaris genomic platform in prostate cancer management.
Honored to have contributed to this international collaborative effort (ASCO-GU 2026!).

[Thomas Zilli @ZilliThomas]

Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a LHRH Antagonist Versus Agonist in with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial
https://t.co/HJBfV4Nhwn @BertrandTOMBAL @EORTC

[Virginia Ruiz @roentgen66]

La verdadera evolución que el cáncer necesita no solo está en la ciencia, sino en la conciencia.
Avanzar tecnológicamente no sirve si olvidamos acompañar, cuidar y escuchar.

🧬✨
Gracias al @Museoevolucion por abrir este espacio
https://t.co/lcUwvBmk7u

#CienciaYConciencia

[Ivan Henriquez @ivanh1960]

I have really enjoyed this meeting!!!

[Virginia Ruiz @roentgen66]

@museoevolucion @ClinicaNavarra Gracias a vosotros por tener el privilegio de abrir este ciclo de charlas sobre el cáncer.

[MuseoEvoluciónHumana @museoevolucion]

Gracias @roentgen66 Virginia Ruiz por la magnífica charla ofrecida para abrir el ciclo sobre Evolucionar contra el cáncer, desde una visión humanista y de atención cercana, incluso en la mejora de las instalaciones. El martes 4 contamos con doctor Calvo de la @ClinicaNavarra

[Ivan Henriquez @ivanh1960]

How we treat high risk patients in Spain 🇪🇸. Uroncor group!.

[Ivan Henriquez @ivanh1960]

How we treat high risk patients in Spain 🇪🇸. Uroncor group!.

[Ivan Henriquez @ivanh1960]

Absolutely agree!!. POP-RT trial at 5yr: WPRT better BF and DFS. 80% underw/PSMA. At 6-yr late G3GU tox similar. I don’t think WPRT is dead yet!.

[Matthew Katz, MD 🇺🇸🟦 @subatomicdoc]

@DrSpratticus @piet_ost @NRGonc Agree. Part of the problem for 0924 may have been that Roach formulas give much higher estimates of nodal risk than nomograms. To test it again means using new nomograms in the post-PSMA PET era.

Postop is a different disease state with a less certainty where the cancer is.